Moderna, Inc.

Moderna, Inc. (NASDAQ: MRNA) is a biotechnology company that specializes in research and development of therapeutics and vaccines for infectious, cardiovascular, immuno-oncology, and auto immune diseases based on messenger RNA (mRNA). Currently, MRNA has 15 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic and cancer vaccines, intratumoral immuno-oncology, and various therapeutics. It has also collaborated with various companies for the manufacturing of COVID-19 vaccines.

Why Should Investors Book Profit?

• Weak Liquidity Profile: The company's current ratio at the end of FY21 is 1.76x, compared to the industry median of 5.98x. This implies relatively lackluster liquidity profile against the industry median.
• Relatively Low Gross Margins: The company is operating at a gross margin of 85.8% in FY21 compared to the industry median of 87.1%.
• Strict Regulatory Risk: MRNA must conduct its business in the ambit of a strict regulatory environment, non-observance of norms could lead to recall or suspension of prior approvals.
• Leveraged Balance Sheet: The company is more exposed to balance sheet risk than its peers, with a Debt/Equity ratio of 0.05x as of December 31, 2021, compared to the industry norm of 0.0x.
• High Cash Conversion Days: Compared to the industry, the company has a long Cash Conversion Cycle (Days), meaning that it takes more days to convert its inventory to cash. In FY21, its Cash Cycle was 128 days, compared to an industry median of 63 days.

Valuation Methodology: EV/Sales Multiple Based Relative Valuation

(Analysis by Kalkine Group)

* % Premium/(Discount) is based on our assessment of the company's FY1 trading multiple after considering its key growth drivers, economic moat, stock's historical trading multiples versus peer average/median, and investment risks.

Stock Recommendation:

MRNA's share price has inclined 54.14% in the past six months and is currently leaning towards the lower band of the 52-week range of USD 119.33 to USD 497.49. We have valued the stock using the EV/Sales-based relative valuation methodology and arrived at a target price of USD 157.60.

Considering the company's industry above leverage, weak liquidity profile, current valuation and associated risks. we recommend a "Sell" rating on the stock at the closing price of USD 172.54, up 2.29% as of April 04, 2022.

1 -Year Technical Price Chart (as of April 04, 2022). Source: REFINITIV, Analysis by Kalkine Group

* The reference data in this report has been partly sourced from REFINITIV.

* All forecasted figures and industry information have been taken from REFINITIV. 

Disclaimer

References to ‘Kalkine’, ‘we’, ‘our’ and ‘us’ refer to Kalkine Limited.

This website is a service of Kalkine Limited. Kalkine Limited is a private limited company, incorporated in England and Wales with registration number 07903332. Kalkine Limited is authorised and regulated by the Financial Conduct Authority under reference number 579414.

The article has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. No advice or information, whether oral or written, obtained by you from Kalkine or through or from the service shall create any warranty not expressly stated. Kalkine does not intend to exclude any liability which it is not permitted to exclude under applicable law or regulation.

Kalkine does not offer financial advice based upon your personal financial situation or goals, and we shall NOT be held liable for any investment or trading losses you may incur by using the opinions expressed in our publications, market updates, news alerts and corporate profiles. Kalkine does not intend to exclude any liability which it is not permitted to exclude under applicable law or regulation. Kalkine’s non-personalised advice does not in any way endorse or recommend individuals, investment products or services for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a professional authorised financial planner and adviser. You should be aware that the value of any investment and the income from it can go down as well as up and you may not get back the amount invested.

Kalkine Media Limited, an affiliate of Kalkine Limited, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.